Ligand Pharmaceuticals Incorporated (LGND) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 3.66B |
| Enterprise Value | 3.93B |
| P/E Ratio | 33.05 |
| PEG Ratio | 0.03 |
| Price/Sales Ratio | 18.64 |
| Price/Book Ratio | 5.09 |
| Enterprise/Revenue | 19.86 |
| Enterprise/EBITDA | 24.53 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0.56 |
| Operating Margin | 0.37 |
| Return On Assets | 0.1 |
| Return On Equity | 0.16 |
| Revenue | 268.09M |
| Revenue/Share | 13.8 |
| Gross Profit | 261.5M |
| EBITDA | 192.74M |
| Net Income | 124.45M |
| Diluted EPS | 6.13 |
| Total Cash | 779.41M |
| Total Cash/Share | 39.2 |
| Total Debt | 451.98M |
| Total Debt/Equity | 0.45 |
| Current Ratio | 21.28 |
| Book Value Per Share | 50.16 |
| 52-Week Change | 126.81 |
| 52-Week High | 259.03 |
| 52-Week Low | 110 |
| Moving Average 50 Days | 228.24 |
| Moving Average 200 Days | 200.34 |
| Average Volume | 219,617 |
| Shares Outstanding | 20.04M |
| % Held by Institutions | 105.43 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1603:1000 |
| Last Split Date | November 02, 2022 |